Activation of the growth hormone receptor

References

• Waters M. The growth hormone receptor. In: Goodman M Handbook of Physiology – Section 7: The Endocrine System. Oxford University Press, NY, USA 445–480 (1999).
   Google Scholar
• Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254(5033), 821–825 (1991).
   PubMed Web of Science ®Google Scholar
• de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255(5042), 306–312 (1992).
   PubMed Web of Science ®Google Scholar
• Brown RJ, Adams JJ, Pelekanos RA et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12(9), 814–821 (2005).
   PubMed Web of Science ®Google Scholar
• Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc. Natl Acad. Sci. USA 99(15), 9858–9863 (2002).
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, Andry JM. Growth hormone (GH), GH receptor, and signal transduction. Mol. Genet. Metab. 71(1–2), 293–314 (2000).
   PubMed Web of Science ®Google Scholar
• Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 256(5064), 1677–1680 (1992).
   PubMed Web of Science ®Google Scholar
• Pearce KH Jr, Cunningham BC, Fuh G, Teeri T, Wells JA. Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. Biochemistry 38(1), 81–89 (1999).
   PubMed Web of Science ®Google Scholar
• Wan Y, McDevitt A, Shen B, Smythe ML, Waters MJ. Increased site 1 affinity improves biopotency of porcine growth hormone. Evidence against diffusion dependent receptor dimerization. J. Biol. Chem. 279(43), 44775–44784 (2005).
   Web of Science ®Google Scholar
• Leung DW, Spencer SA, Cachianes G et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330(6148), 537–543 (1987).
   PubMed Web of Science ®Google Scholar
• Bazan JF. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain. Biochem. Biophys. Res. Commun. 164(2), 788–795 (1989).
   PubMed Web of Science ®Google Scholar
• Carter-Su C, Stubbart JR, Wang XY, Stred SE, Argetsinger LS, Shafer JA. Phosphorylation of highly purified growth hormone receptors by a growth hormone receptor-associated tyrosine kinase. J. Biol. Chem. 264(31), 18654–18661 (1989).
   PubMed Web of Science ®Google Scholar
• Govers R, ten Broeke T, van Kerkhof P, Schwartz AL, Strous GJ. Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor. Embo. J. 18(1), 28–36 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 141(12), 4342–4348 (2000).
   PubMed Web of Science ®Google Scholar
• Cowan JW, Wang X, Guan R et al. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J. Biol. Chem. 280(19), 19331–19342 (2005).
   PubMed Web of Science ®Google Scholar
• Baumbach WR, Horner DL, Logan JS. The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor. Genes Dev. 3(8), 1199–1205 (1989).
   PubMed Web of Science ®Google Scholar
• Smith WC, Kuniyoshi J, Talamantes F. Mouse serum growth hormone (GH) binding protein has GH receptor extracellular and substituted transmembrane domains. Mol. Endocrinol. 3(6), 984–990 (1989).
   PubMed Web of Science ®Google Scholar
• Baumann G. Growth hormone binding protein 2001. J. Pediatr. Endocrinol. Metab. 14(4), 355–375 (2001).
   PubMed Web of Science ®Google Scholar
• Chen C, Brinkworth R, Waters MJ. The role of receptor dimerization domain residues in growth hormone signaling. J. Biol. Chem. 272(8), 5133–5140 (1997).
   PubMed Web of Science ®Google Scholar
• Duquesnoy P, Sobrier ML, Duriez B et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. Embo. J. 13(6), 1386–1395 (1994).
   PubMed Web of Science ®Google Scholar
• Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J. Biol. Chem. 271(12), 6708–6712 (1996).
   PubMed Web of Science ®Google Scholar
• Ross RJ, Leung KC, Maamra M et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab. 86(4) 1716–1723 (2001).
   PubMed Web of Science ®Google Scholar
• Rowlinson SW, Behncken SN, Rowland JE et al. Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J. Biol. Chem. 273(9), 5307–5314 (1998).
   PubMed Web of Science ®Google Scholar
• Mellado M, Rodriguez-Frade JM, Kremer L et al. Conformational changes required in the human growth hormone receptor for growth hormone signaling. J. Biol. Chem. 272(14), 9189–9196 (1997).
   PubMed Web of Science ®Google Scholar
• Kubatzky KF, Ruan W, Gurezka R et al. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr. Biol. 11(2), 110–115 (2001).
   PubMed Web of Science ®Google Scholar
• Blott S, Kim JJ, Moisio S, Schmidt-Kuntzel A et al. Molecular dissection of a quantitative trait locus: a phenylalanine-to-tyrosine substitution in the transmembrane domain of the bovine growth hormone receptor is associated with a major effect on milk yield and composition. Genetics 163(1), 253–266 (2003).
   PubMed Web of Science ®Google Scholar
• Eidne KA, Kroeger KM, Hanyaloglu AC. Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells. Trends Endocrinol. Metab. 13(10), 415–421 (2002).
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283(5404), 987–990 (1999).
   PubMed Web of Science ®Google Scholar
• Bernat B, Pal G, Sun M, Kossiakoff AA. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Proc. Natl Acad. Sci. USA 100(3), 952–957 (2003).
   PubMed Web of Science ®Google Scholar
• Seubert N, Royer Y, Staerk J et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12(5), 1239–1250 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang J, Kopchick JJ, Frank SJ. Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J. Biol. Chem. 274(46), 33072–33084 (1999).
   PubMed Web of Science ®Google Scholar
• Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J. Mol. Endocrinol. 36(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283(5404), 990–993 (1999).
   PubMed Web of Science ®Google Scholar
• Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35(5), 1681–1691 (1996).
   PubMed Web of Science ®Google Scholar
• Syed RS, Reid SW, Li C et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395(6701), 511–516 (1998).
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273(5274), 464–471 (1996).
   PubMed Web of Science ®Google Scholar
• Livnah O, Johnson DL, Stura EA et al. An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struct. Biol. 5(11), 993–1004 (1998).
   PubMedGoogle Scholar
• Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol. Cell 7(2), 377–385 (2001).
   PubMed Web of Science ®Google Scholar
• Langosch D, Brosig B, Kolmar H, Fritz HJ. Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator. J. Mol. Biol. 263(4), 525–530 (1996).
   PubMed Web of Science ®Google Scholar
• Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl Acad. Sci. USA 98(8), 4379–4384 (2001).
   PubMed Web of Science ®Google Scholar
• Brisken C, Socolovsky M, Lodish HF, Weinberg R. The signaling domain of the erythropoietin receptor rescues prolactin receptor-mutant mammary epithelium. Proc. Natl Acad. Sci. USA 99(22), 14241–14245 (2002).
   PubMed Web of Science ®Google Scholar
• Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 311(5), 1011–1026 (2001).
   PubMed Web of Science ®Google Scholar
• Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 14(6), 687–696 (1997).
   PubMed Web of Science ®Google Scholar
• Burke CL, Stern DF. Activation of neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol. Cell Biol. 18(9), 5371–5379 (1998).
   PubMed Web of Science ®Google Scholar
• Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J. Biol. Chem. 277(7), 4704–4712 (2002).
   PubMed Web of Science ®Google Scholar
• Gerber D, Sal-Man N, Shai Y. Two motifs within a transmembrane the other for heterodimerization. J. Biol. Chem. 279(20), 21177–21182 (2004).
   PubMed Web of Science ®Google Scholar
• VanderKuur J, Allevato G, Billestrup N, Norstedt G, Carter-Su C. Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2. J. Biol. Chem. 270(13), 7587–7593 (1995).
   PubMed Web of Science ®Google Scholar
• Gallego MI, Binart N, Robinson GW et al. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev. Biol. 229(1), 163–175 (2001).
   PubMed Web of Science ®Google Scholar
• Ihle JN. STATs: signal transducers and activators of transcription. Cell 84(3), 331–334 (1996).
   PubMed Web of Science ®Google Scholar
• Rowland JE, Lichanska AM, Kerr LM et al. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol. Cell Biol. 25(1), 66–77 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu T, Ling L, Lobie PE. Identification of a JAK2 independent pathway regulating growth hormone (GH) stimulated p44/42 MAP kinase activity: GH activation of RAL and phospholipase D is Src dependent. J. Biol. Chem. 5, 5 (2002).
   Google Scholar
• Yamauchi T, Kaburagi Y, Ueki K et al. Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3- kinase activation via JAK2 kinase. J. Biol. Chem. 273(25), 15719–15726 (1998).
   PubMed Web of Science ®Google Scholar
• Kofoed EM, Hwa V, Little B et al. Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349(12), 1139–1147 (2003).
   PubMed Web of Science ®Google Scholar
• Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm. Res. 56(Suppl. 1), 13–18 (2001).
   PubMedGoogle Scholar
• Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int. J. Cardiol. 85(1), 151–159 (2002).
   PubMed Web of Science ®Google Scholar
• Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc. Res. 54(1), 25–35 (2002).
   PubMed Web of Science ®Google Scholar
• Bryant J, Loveman E, Cave C, Chase D, Milne R. Endocrinology trial design: adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adults. J. Endocrinol. 175(2), 545–552 (2002).
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Romijn JA, Pereira AM. Treatment strategies for acromegaly. Expert Opin. Emerg. Drugs 10(4), 875–890 (2005).
   PubMedGoogle Scholar
• Hardin DS, Ferkol T, Ahn C et al. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clin. Endocrinol. (Oxf) 62(5), 560–566 (2005).
   PubMed Web of Science ®Google Scholar
• Yin MT, Glesby MJ. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity. Expert Rev. Anti Infect. Ther. 3(5), 727–738 (2005).
   Google Scholar
• Hardin DS, Rice J, Doyle ME, Pavia A. Growth hormone improves protein catabolism and growth in prepubertal children with HIV infection. Clin. Endocrinol. (Oxf) 63(3), 259–262 (2005).
   PubMed Web of Science ®Google Scholar
• Bocchi E, Moura L, Guimaraes G, Conceicao Souza GE, Ramires JA. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int. J. Cardiol. 12, 12 (2005).
   Google Scholar
• Jayasankar V, Pirolli TJ, Bish LT et al. Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy. J. Mol. Cell Cardiol. 36(4), 531–538 (2004).
   PubMed Web of Science ®Google Scholar
• Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab.90(3), 1466–1474 (2005) (In Press).
   PubMed Web of Science ®Google Scholar
• Nam SY, Kim KR, Cha BS et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 25(8), 1101–1107 (2001).
   PubMed Web of Science ®Google Scholar
• Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S. Role of growth hormone (GH) in liver regeneration. Endocrinology 145(10), 4748–4755 (2004).
   PubMed Web of Science ®Google Scholar
• Beyea JA, Sawicki G, Olson DM, List E, Kopchick JJ, Harvey S. Growth hormone (GH) receptor knockout mice reveal actions of GH in lung development. Proteomics 6(1), 341–348 (2005).
   Google Scholar
• Smid JR, Rowland JE, Young WG et al. Mouse cellular cementum is highly dependent on growth hormone status. J. Dent. Res. 83(1), 35–39 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis MD, Horan M, Millar DS et al. A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J. Clin. Endocrinol. Metab. 89(3), 1068–1075 (2004).
   PubMed Web of Science ®Google Scholar
• Rowland JE, Marshall NJ, Leung KC et al. Novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays. Clin Endocrinol. (Oxf) 56(4), 475–485 (2002).
   PubMed Web of Science ®Google Scholar
• Smith LE, Kopchick JJ, Chen W et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276(5319), 1706–1709 (1997).
   PubMed Web of Science ®Google Scholar
• Growth Hormone Antagonistfor Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108(12), 2266–2272 (2001).
   PubMed Web of Science ®Google Scholar
• Doi T, Striker LJ, Quaife C et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor-1. Am. J. Pathol. 131(3), 398–403 (1988).
   PubMed Web of Science ®Google Scholar
• Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. Clinical review 166: growth hormone receptor antagonists. J. Clin. Endocrinol. Metab. 89(4), 1503–1511 (2004).
   PubMed Web of Science ®Google Scholar
• Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc. Natl Acad. Sci. USA 101(42), 15166–15171 (2004).
   PubMed Web of Science ®Google Scholar
• Raccurt M, Lobie PE, Moudilou E et al. High stromal and epithelial human GH gene expression is associated with proliferative disorders of the mammary gland. J. Endocrinol. 175(2), 307–318 (2002).
   PubMed Web of Science ®Google Scholar
• Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br. J. Cancer 85(3), 428–430 (2001).
   PubMed Web of Science ®Google Scholar
• Swanson SM, Unterman TG. The growth hormone-deficient spontaneous dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 23(6), 977–982 (2002).
   PubMed Web of Science ®Google Scholar
• Wang Z, Prins GS, Coschigano KT et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the c3(1)/t antigen mouse. Endocrinology 146(12), 5188–5196 (2005).
   PubMed Web of Science ®Google Scholar
• McCutcheon IE, Flyvbjerg A, Hill H et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J. Neurosurg. 94(3), 487–492 (2001).
   PubMed Web of Science ®Google Scholar
• Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE, Flyvbjerg A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res. 24(6), 3735–3742 (2004).
   PubMed Web of Science ®Google Scholar
• Rowlinson SW, Waters MJ, Lewis UJ, Barnard R. Human growth hormone fragments 1–43 and 44–191: in vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems. Endocrinology 137(1), 90–95 (1996).
   PubMed Web of Science ®Google Scholar
• Ohkura K, Hori H. Analyses of insulin-potentiating fragments of human growth hormone by computative simulation; essential unit for insulin-involved biological responses. Bioorg. Med. Chem. 8(7), 1733–1740 (2000).
   PubMed Web of Science ®Google Scholar
• De Palo EF, Gatti R, Antonelli G, Spinella P. Growth hormone isoforms, segments/fragments: does a link exist with multifunctionality? Clin. Chim. Acta 364(1–2), 77–81 (2005).
   Web of Science ®Google Scholar
• Qureshi SA, Kim RM, Konteatis Z et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc. Natl Acad. Sci. USA 96(21), 12156–12161 (1999).
   PubMed Web of Science ®Google Scholar
• Boger DL, Goldberg J. Cytokine receptor dimerization and activation: prospects for small molecule agonists. Bioorg. Med. Chem. 9(3), 557–562 (2001).
   PubMed Web of Science ®Google Scholar
• Tachas G, Lofthouse S, Wraight C et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-1 production and body weight gain in normal mice. J. Endocrinol. (2005) (In Press).
   Google Scholar